French MedTech Powerhouse Sofinnova Secures €650 Million for Fund XI, Bolstering €4 Billion AUM

Sofinnova Partners, a prominent Paris-based venture capital firm, recently announced the successful closure of its latest flagship fund, Sofinnova Capital XI, at an impressive €650 million. This amount exceeded the original target and reaffirmed the firm’s position as a key player in life sciences investment.

The new fund received support from a diverse group of top-tier institutional investors globally, including sovereign wealth funds, pharmaceutical companies, insurance firms, foundations, and family offices. Notably, the British Business Bank committed €30 million to the fund, aligning with the UK government’s Life Sciences Sector Plan.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, expressed excitement about the fundraising milestone, stating that it provides the firm with the resources to focus on early-stage opportunities and strengthen its collaborative, science-driven investment approach. The goal is to support visionary entrepreneurs and advance breakthroughs in science and medicine for the benefit of patients worldwide.

In 2025, EU-Startups reported significant funding rounds in the life sciences and health sectors across Europe. For example, France’s Adcytherix secured €105 million for its cancer therapy, while Sweden’s Cellcolabs raised €10.3 million to scale manufacturing of stem cells. Additionally, Switzerland’s arcoris bio closed a €6.7 million Seed round for its biomarker detection technology.

These disclosed funding rounds totaled approximately €121 million, highlighting substantial activity at the startup level but falling short of Sofinnova’s recent fund size. The data also indicated a period of active innovation in French life sciences in 2025.

Papiernik emphasized the strength of Sofinnova’s model and the continued confidence of investors in the firm, despite the volatile fundraising environment. Founded in 1972, Sofinnova Partners has a strong legacy and a portfolio of over 500 companies, with offices in Paris, London, and Milan.

The firm’s new fund aims to support early-stage biopharmaceutical and MedTech startups addressing unmet clinical needs in Europe and North America. This underscores a continued interest in scientific innovation during challenging times.

Sofinnova Capital XI is already investing in select companies, reflecting the firm’s active participation in funding rounds and its mission to translate research into impactful therapies and technologies.

Mark Andrews, Investment Director, Funds, Life Sciences at the British Business Bank, praised Sofinnova as a key player in life sciences venture and highlighted the importance of their commitment to UK life sciences. He expressed excitement about the potential breakthroughs that may result from the fund.

The launch of Sofinnova Capital XI solidifies the firm’s role as a cornerstone investor in early-stage BioTech and MedTech ventures. With total capital raised across Sofinnova’s platform reaching €1.5 billion, the firm is well-positioned to drive scientific advances and commercial success for healthcare innovators.

Christine Hockley, Managing Director and Co-Head of Funds, emphasized the firm’s activity in the UK life sciences sector and the importance of investing in innovative companies at every stage of growth. She highlighted the need for funds like Sofinnova Capital XI to provide essential funding for high-potential companies.

In conclusion, Sofinnova Partners’ latest fund underscores its commitment to supporting groundbreaking research and driving innovation in the life sciences sector. With a strong track record and international investor support, the firm is poised to contribute to the success of the next generation of healthcare innovators.